


**Product Name** : ASK120067  
**Cat. No.** : PC-38347  
**CAS No.** : 1934259-00-3  
**Molecular Formula** : C<sub>29</sub>H<sub>32</sub>ClN<sub>7</sub>O<sub>2</sub>  
**Molecular Weight** : 546.072  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



## Biological Activity

ASK120067 (Limertinib) is a novel third-generation inhibitor of **EGFR T790M** (L858R/T790M IC<sub>50</sub>=0.3 nM, T790M IC<sub>50</sub>=0.5 nM), with selectivity over EGFR WT (IC<sub>50</sub>=6 nM).

ASK120067 potently inhibited the EGFR L858R/T790M and EGFR T790M resistant mutants, with IC<sub>50</sub> of 0.3 nM and 0.5 nM, respectively, as well as the EGFR exon19del sensitizing mutant (IC<sub>50</sub>= 0.5 nM).

ASK120067 also displayed a favorable selectivity profile against a panel of 258 kinases.

ASK120067 selectively inhibits the growth of EGFR-mutant cell lines and induces apoptosis, with IC<sub>50</sub> values of 12 nM, 6 nM and 2 nM against NCI-H1975, PC-9, and HCC827 cells, respectively.

ASK120067 dose-dependently inhibited EGF-induced EGFR L858R/T790M phosphorylation and consequent activation of the downstream molecules AKT and ERK in NCI-H1975 cells, with similar or even more effective potency than osimertinib.

ASK120067 (5, 10 mg/kg once daily) demonstrated profound and selective antitumor efficacy in EGFR-mutant xenograft models in vivo.

## References

Zhang T, et al. *Mol Cancer*. 2020 May 13;19(1):90.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com